









Markets
/
Stocks
/
nasdaq-rcel
/

AVITA Medical Inc

RCEL

3.820USD

-0.040-1.04%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

583.92MMarket Cap

LossP/E TTM



AVITA Medical Inc

3.820

-0.040-1.04%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of AVITA Medical Inc

Currency: USD Updated: 2026-03-27

Key Insights

AVITA Medical Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 136 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.40.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AVITA Medical Inc's Score

Industry at a Glance

Industry Ranking

136 / 391

Overall Ranking

258 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

AVITA Medical Inc Highlights

StrengthsRisks

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 42.81% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 71.61M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 71.61M.

Overvalued

The company’s latest PE is -2.19, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.28M shares, decreasing 44.16% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.44M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.99.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

6.400

Target Price

+65.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of AVITA Medical Inc is 6.78, ranking 203 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 17.61M, representing a year-over-year decrease of 4.30%, while its net profit experienced a year-over-year decrease of 0.28%.

Score

Industry at a Glance

Previous score

6.78

Change



Financials

4.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.13

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.59

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.18

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.18

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

AVITA Medical Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of AVITA Medical Inc is 6.98, ranking 190 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.19, which is -21.01% below the recent high of -1.73 and -681.94% above the recent low of -17.13.

Score

Industry at a Glance

Previous score

6.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 136/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of AVITA Medical Inc is 7.67, ranking 274 out of 391 in the Biotechnology & Medical Research industry. The average price target is 5.50, with a high of 14.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

7.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

6.400

Target Price

+65.80%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

AVITA Medical Inc

RCEL

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of AVITA Medical Inc is 6.27, ranking 250 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.02 and the support level at 3.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.15

Change

0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.203

Sell

RSI(14)

37.456

Neutral

STOCH(KDJ)(9,3,3)

21.751

Neutral

ATR(14)

0.302

High Vlolatility

CCI(14)

-102.034

Sell

Williams %R

81.875

Oversold

TRIX(12,20)

-0.588

Sell

StochRSI(14)

26.953

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.892

Sell

MA10

4.072

Sell

MA20

4.446

Sell

MA50

4.364

Sell

MA100

3.968

Sell

MA200

4.537

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of AVITA Medical Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 17.32%, representing a quarter-over-quarter decrease of 31.17%. The largest institutional shareholder is The Vanguard, holding a total of 1.44M shares, representing 4.72% of shares outstanding, with 13.06% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.37M

-5.85%

BlackRock Institutional Trust Company, N.A.

1.07M

-38.45%

Geode Capital Management, L.L.C.

331.46K

-46.39%

State Street Investment Management (US)

423.31K

-19.95%

Northern Trust Investments, Inc.

158.78K

-34.40%

Bridgeway Capital Management, LLC

118.00K

+213.84%

AQR Capital Management, LLC

119.29K

+444.12%

Divisadero Street Capital Management, LP

100.00K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AVITA Medical Inc is 2.77, ranking 198 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.87. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.